Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Moshe Talpaz

Showing results (211-220 of 264) with videos related to

Pageof 27
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 13, 2002
Treatment of philadelphia chromosome-positive, accelerated-phase chronic myelogenous leukemia with imatinib mesylateHagop M Kantarjian, Susan O'Brien, Jorge E Cortes, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|December 1, 2005
Chronic myelogenous leukemiaSusan O'Brien, Ellin Berman, Kapil Bhalla, et al.
Cancer Cell|March 31, 2015
Pharmacologic inhibition of the Menin-MLL interaction blocks progression of MLL leukemia in vivoDmitry Borkin, Shihan He, Hongzhi Miao, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|May 19, 2007
Chronic myelogenous leukemiaSusan O'Brien, Ellin Berman, Kapil Bhalla, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|November 3, 2009
NCCN clinical practice guidelines in oncology: chronic myelogenous leukemiaSusan O'Brien, Ellin Berman, Hossein Borghaei, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 13, 2002
Imatinib mesylate for Philadelphia chromosome-positive, chronic-phase myeloid leukemia after failure of interferon-alpha: follow-up resultsHagop M Kantarjian, Moshe Talpaz, Susan O'Brien, et al.
Blood|November 26, 2015
Compound mutations in BCR-ABL1 are not major drivers of primary or secondary resistance to ponatinib in CP-CML patientsMichael W Deininger, J Graeme Hodgson, Neil P Shah, et al.
Blood|August 18, 2021
Ponatinib dose-ranging study in chronic-phase chronic myeloid leukemia: a randomized, open-label phase 2 clinical trialJorge Cortes, Jane Apperley, Elza Lomaia, et al.
Journal of Hematology & Oncology|November 29, 2013
Interim analysis of safety and efficacy of ruxolitinib in patients with myelofibrosis and low platelet countsMoshe Talpaz, Ronald Paquette, Lawrence Afrin, et al.
Nature Genetics|January 15, 2013
Identification of recurrent NAB2-STAT6 gene fusions in solitary fibrous tumor by integrative sequencingDan R Robinson, Yi-Mi Wu, Shanker Kalyana-Sundaram, et al.
Pageof 27

Showing results (211-220 of 264) with videos related to

Sort By:
Pageof 27
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 13, 2002
Treatment of philadelphia chromosome-positive, accelerated-phase chronic myelogenous leukemia with imatinib mesylateHagop M Kantarjian, Susan O'Brien, Jorge E Cortes, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|December 1, 2005
Chronic myelogenous leukemiaSusan O'Brien, Ellin Berman, Kapil Bhalla, et al.
Cancer Cell|March 31, 2015
Pharmacologic inhibition of the Menin-MLL interaction blocks progression of MLL leukemia in vivoDmitry Borkin, Shihan He, Hongzhi Miao, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|May 19, 2007
Chronic myelogenous leukemiaSusan O'Brien, Ellin Berman, Kapil Bhalla, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|November 3, 2009
NCCN clinical practice guidelines in oncology: chronic myelogenous leukemiaSusan O'Brien, Ellin Berman, Hossein Borghaei, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 13, 2002
Imatinib mesylate for Philadelphia chromosome-positive, chronic-phase myeloid leukemia after failure of interferon-alpha: follow-up resultsHagop M Kantarjian, Moshe Talpaz, Susan O'Brien, et al.
Blood|November 26, 2015
Compound mutations in BCR-ABL1 are not major drivers of primary or secondary resistance to ponatinib in CP-CML patientsMichael W Deininger, J Graeme Hodgson, Neil P Shah, et al.
Blood|August 18, 2021
Ponatinib dose-ranging study in chronic-phase chronic myeloid leukemia: a randomized, open-label phase 2 clinical trialJorge Cortes, Jane Apperley, Elza Lomaia, et al.
Journal of Hematology & Oncology|November 29, 2013
Interim analysis of safety and efficacy of ruxolitinib in patients with myelofibrosis and low platelet countsMoshe Talpaz, Ronald Paquette, Lawrence Afrin, et al.
Nature Genetics|January 15, 2013
Identification of recurrent NAB2-STAT6 gene fusions in solitary fibrous tumor by integrative sequencingDan R Robinson, Yi-Mi Wu, Shanker Kalyana-Sundaram, et al.
Pageof 27